3 Drugs Stocks On The Rise

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 30 points (0.2%) at 16,949 as of Wednesday, Aug. 20, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,346 issues advancing vs. 1,589 declining with 185 unchanged.

The Drugs industry currently sits down 0.3% versus the S&P 500, which is up 0.1%. Top gainers within the industry include Jazz Pharmaceuticals ( JAZZ), up 2.7%, Dr Reddy Laboratories ( RDY), up 2.5%, Biomarin Pharmaceutical ( BMRN), up 2.5%, Illumina ( ILMN), up 2.2% and Novo Nordisk A/S ( NVO), up 0.8%. On the negative front, top decliners within the industry include Idexx Laboratories ( IDXX), down 3.2%, Sanofi ( SNY), down 1.0% and Alexion Pharmaceuticals ( ALXN), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Teva Pharmaceutical Industries ( TEVA) is one of the companies pushing the Drugs industry higher today. As of noon trading, Teva Pharmaceutical Industries is up $0.39 (0.7%) to $53.18 on light volume. Thus far, 1.3 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4.1 million shares. The stock has ranged in price between $52.42-$53.40 after having opened the day at $52.52 as compared to the previous trading day's close of $52.79.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $44.7 billion and is part of the health care sector. Shares are up 31.7% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts who rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, attractive valuation levels, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Teva Pharmaceutical Industries Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Celgene ( CELG) is up $1.50 (1.6%) to $92.86 on average volume. Thus far, 2.7 million shares of Celgene exchanged hands as compared to its average daily volume of 4.7 million shares. The stock has ranged in price between $91.11-$93.35 after having opened the day at $91.33 as compared to the previous trading day's close of $91.36.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene has a market cap of $73.0 billion and is part of the health care sector. Shares are up 8.1% year-to-date as of the close of trading on Tuesday. Currently there are 17 analysts who rate Celgene a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, robust revenue growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Celgene Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Merck ( MRK) is up $0.46 (0.8%) to $59.36 on light volume. Thus far, 3.0 million shares of Merck exchanged hands as compared to its average daily volume of 8.3 million shares. The stock has ranged in price between $58.53-$59.40 after having opened the day at $58.68 as compared to the previous trading day's close of $58.91.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $168.5 billion and is part of the health care sector. Shares are up 17.7% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts who rate Merck a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, solid stock price performance, reasonable valuation levels, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Merck Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Tuesday Turnaround in Politics: Is a Trade War on the Horizon?

Tuesday Turnaround in Politics: Is a Trade War on the Horizon?

FANG Stocks Get Swept Up in Broader Market Selloff

FANG Stocks Get Swept Up in Broader Market Selloff

Snap Shares Plunge After Cowen Cuts Price Target

Snap Shares Plunge After Cowen Cuts Price Target

Netflix Shares Hit All-Time High as Market Flounders

Netflix Shares Hit All-Time High as Market Flounders